Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05156697 |
| Other study ID # |
839/CEIH/2019 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
June 3, 2019 |
| Est. completion date |
July 1, 2020 |
Study information
| Verified date |
December 2021 |
| Source |
Universidad de Granada |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Prior evidence suggests that capsinoids ingestion may increase resting energy expenditure
(EE) and fat oxidation (FATox) in humans, although whether they can modulate those parameters
during exercise conditions remains poorly understood. Investigators aimed to determine the
effects of dihydrocapsiate (DHC) ingestion on EE and FATox during an acute bout of aerobic
exercise at FATmax intensity (the intensity that elicits maximal fat oxidation [MFO] during
exercise) in overweight/obese men.
A total of 24 sedentary overweight/obese men participated in this randomized, triple-blinded,
placebo-controlled, crossover trial. On the first day, participants underwent a submaximal
exercise test in a cycloergometer to determine their MFO and FATmax intensity during
exercise. After 72 hours had elapsed, the participants returned in 2 further days (≥ 72 hours
apart) and performed a 60 min steady-state test (SST, i.e., cycling at their FATmax, constant
intensity) after ingesting either 12 mg of DHC or placebo; these conditions were randomized.
Respiratory gas exchange was monitored by indirect calorimetry. Serum markers concentrations
(glucose, triglycerides, and non-esterified fatty acids), skin temperature, thermal
perception, heart rate and perceived fatigue were assessed as secondary outcomes.
Description:
The study protocol and design have been approved by the Human Research Ethics Committee of
the University of Granada (n°839/CEIH/2019) and the Servicio Andaluz de Salud and adhered to
the tenets of the Declaration of Helsinki as revised in 2013.
Participants were asked to confirm having commuted to the research center by car, bus, tram,
or motorcycle, having slept, as usual, having refrained from stimulant beverages within 24 h,
and having avoided any moderate or vigorous physical activity within 24 h and 48 h
(respectively).
METHODS SUMMARY
Briefly, in the first visit, sociodemographic and lifestyle data were registered, and medical
screening was performed, blood samples were collected, and anthropometry and body composition
measures were taken. On the second visit, the MFO during exercise and cardiorespiratory
fitness (peak volume of oxygen consumption, VO2 peak) were respectively assessed through a
submaximal exercise test coupled to a maximal effort test. On visits third and fourth,
participants performed a 60 min steady-state exercise bout on a cycle ergometer at FATmax
intensity (i.e., at the intensity at which MFO is elicited) after having ingested either 12
mg of DHC or placebo. The conditions (DHC or placebo) on visits 3 and 4 were randomized. The
washout period between visits 3 and 4 was ≥72 h. Of note, all exercise tests took place at a
strictly controlled temperature of 22-23 ºC, given that environmental temperature largely
influences EE and FATox.
EXTENDED METHODS
MEDICAL SCREENING, SOCIODEMOGRAPHIC DATA COLLECTION, AND ANTHROPOMETRY AND BODY COMPOSITION
ASSESSMENTS:
On the first visit, participants arrived at the research center at 08:00 h, in fasting
conditions (8 h). Participants were informed about the study protocols details and gave their
oral and written informed consent to participate in the study. Sociodemographic data and data
related to participants´ dietary habits (including pungent consumption), appetite, physical
activity levels, sleep, and other lifestyle habits were recorded by questionnaires (some of
them filled at home). Afterward, a medical doctor conducted an anamnesis to ensure that each
participant was in suitable physical conditions to participate in the study and to practice
exercise. Next, participants underwent an electrocardiogram in resting conditions, which was
conducted by an expert medical doctor. Systolic and diastolic blood pressure were also
measured with an automatic sphygmomanometer (Omron M2; Omron Healthcare, Kyoto, Japan). These
measurements were repeated on 3 consecutive occasions and the average systolic and diastolic
blood pressure were calculated. Only participants presenting a non-risk medical history and
normal electrocardiogram were allowed to participate in the study. Blood samples were
collected from the antecubital vein in the morning (8.00-9.00 am), with subjects sitting and
in resting conditions. Blood samples were collected in serum Vacutainer Tubes® (Vacutainer®
SST™ II Advance tubes) and centrifuged following the manufacturer's instructions. Afterward,
serum samples were sent to the hospital lab for the analysis of the analytes of interest.
Anthropometry and body composition assessments also took place on the first visit. Body
weight and height were measured (no shoes, light clothing) using a model 799 Seca scale and
stadiometer (Seca, Hamburg, Germany). Waist circumference was measured twice at the minimum
perimeter area with a measuring tape (mm precision), and the mean value was calculated. For
those participants with abdominal obesity, waist circumference was measured just above the
umbilicus (horizontal plane). Body fat mass and percentage, lean body mass, and visceral
adipose tissue (VAT) mas were then measured by whole-body dual-energy X-ray absorptiometry
(HOLOGIC, Discovery Wi, Marlborough, MA). Body mass, lean mass, and fat mass indexes were
calculated as kg/m2.
SUBMAXIMAL AND MAXIMAL EXERCISE TESTS:
On the second visit, individuals arrived at the research center normally between 15:30 and
19:00. Participants confirmed having met the above-stated pre-experimental conditions, as
well as arriving in fasting conditions (5-6 h) and having followed a standardized diet that
participants were instructed to follow during the previous day. Then, participants urinated,
dressed as above, and entered a quiet, warm (22-23 °C) room. A submaximal-graded exercise
test was performed (to determine the MFO) coupled to a maximum effort test (used to determine
the VO2peak) employing an Ergoselect 200 cycle ergometer (Ergoline GmbH, Lindenstrasse,
Germany). More in detail, the submaximal exercise protocol coupled to indirect calorimetry
started with a 3 min stage at 20 watts (W) as a warm-up, followed by increments of 20 W every
3 min, until resting exchange ratio (RER) was ≥1 at least for 30 s (as determined by indirect
calorimetry). At this point, the maximal exercise protocol started (with no interruptions),
and increments of 20 W took place every 1 min until volitional exhaustion was reached, or
participants had to stop because of peripherical fatigue. Of note, the cycling power values
(W) at which MFO happened for each individual were used as the target exercise intensity
(i.e. FATmax) for the subsequent steady-state tests. Through the exercise test, participants'
perceived fatigue was assessed using a rating of the reported perceived exertion (RPE) scale,
and heart rate was measured using a Polar RS800 heart-rate monitor (Polar Electro Inc.,
Woodbury, NY, USA). Respiratory gas exchange was monitored with a CPX Ultima CardioO2 system
(Medical Graphics Corp., St Paul, MN) with a facemask model 7400 (Hans Rudolph Inc., Kansas
City, MO), and a preVent™ metabolic flow sensor (Medical Graphics Corp.). Oxygen consumption
(VO2) was measured using a galvanic fuel cell and carbon dioxide production (VCO2) was
assessed using a non-dispersive infrared sensor. According to the manufacturer's
recommendations, the gas analyzer was calibrated using standard gas concentrations
immediately before each test.
STEADY-STATE EXERCISE TESTS:
On the third visit (≥72 h after the second day), and again on the fourth visit (≥72 h later
to avoid carry-out effects), participants came to the laboratory and underwent the
steady-state tests after the ingestion of DHC or placebo, in a randomized order. Participants
arrived at the same time as on the second visit and confirmed having met exactly the same
pre-experimental conditions. Participants urinated, dressed in standard clothing, and entered
a quiet, warm (22-23 °C) room. A Polar RS800 heart-rate monitor was placed on their chest
using a chest wrap band. Then, a set of 16 DS-1922 L Button TM wireless thermometers
(Thermochron, Dallas, TX, USA) were attached to the subject's skin in different places to
monitor skin temperature changes through the experiment. They were put on the forehead, left
pectoralis, left elbow region, left index fingertip, left forearm, rear neck central area,
right clavicula, right deltoid, right shinbone, right sub-clavicular area, right
supra-clavicular area, right thigh, and upper breastbone. Afterward, participants sat and
stay relaxed for 10 min (resting period, timepoint -20´), and were instructed not to move nor
cross their arms and legs, and their baseline skin temperature and heart rate measures were
taken. The first intravenous blood sample was collected 10 min before starting the
steady-state test (timepoint -10'). Immediately 3 min after the first blood collection
(timepoint -7'), participants ingested either 12 mg of DHC (4 pills 3 mg each one) or
placebo. Then participants sat in the cycle ergometer where the steady-state tests would be
performed, and a gas mask was put on for the gases exchange measurement. The same metabolic
cart as on the second visit was used. The gas collection started 1 min before the beginning
of the steady-state test (timepoint -1') with the participants sitting in the cycle ergometer
without pedaling. After 1 min of gases recording in resting conditions, the steady-state test
at FATmax intensity started and continued until min 60, the moment at which the test was
ended. Gases exchange and heart rate were continuously monitored. At time points 15', 30',
45', and 60', blood samples were collected.
TEST SUBSTANCES: DIHYDROCAPSIATE AND PLACEBO:
Investigators employed Capsiate Gold™ soft-gel capsules from Ajinomoto®. These capsules
consisted of 3 mg of purified DHC vehiculated with canola oil, modified corn starch,
vegetable glycerin, carrageenan, water, disodium hydrogen phosphate, and soy lecithin.
Hemicellulose powder was used as a placebo. Both DHC and hemicellulose were encapsulated by
independent manufacturers and put in different containers by an independent researcher (not
involved in the current study). Each container was labeled with a different code (0 or 1) so
that evaluators were not aware of the administered substance - therefore preventing bias. Of
note, both DHC and placebo capsules looked exactly similar to unable the identification of
the content by either researchers or participants.
